



ASX Release

Jayex completes \$700K capital raise

Highlights

- \$700,000 raised in a placement to institutional and sophisticated investors at 2.8c per new share representing an 11% discount to the 15 day VWAP.
- Funding supports rollout of new products for Jayex Connect Platform
- Funding allows due diligence and assessment of potential strategic acquisitions

Melbourne, Australia 2nd September 2020: – **Jayex Healthcare (ASX:JHL) (Jayex or Company)**, a leading UK and Australian e-health provider of integrated SaaS healthcare services delivery platforms, is pleased to announce the successful completion of a placement of 25,000,000 shares at 2.8c per new share, raising a total of \$700,000.

The raise, which was strongly supported by new and existing investors, ensures that Jayex is able to pursue its two-pronged growth strategy. Jayex is focused on innovation and expanding the capabilities available on its Jayex Connect platform which is used by more than 3250 GP clinics and hospitals across the UK, Australia and New Zealand.

Remote patient monitoring is at the forefront of this product expansion and the funds will be in part used to for the sales and marketing of newly released applications. This includes the imminent rollout of a new application for monitoring of fever and flu-like symptoms, which the company has licensed from Lifespot Health.

Jayex is also looking to expand via acquisition and the funds raised will allow due diligence and the assessment of potential strategic acquisitions.

“Jayex is a highly trusted and well-known brand with a 40 year heritage. That puts us in a unique and trusted position to introduce our customers to new solutions, fit for the modern delivery of healthcare and present a fresh offering to the broader market. Our transition to a cloud-based model is allowing us to evolve the platform, deploy new products rapidly, and ultimately create the opportunity to grow revenue by deepening our relationship with our long-standing existing customer base, and continue to expand into new sites.

“The capital raise provides working capital to support our sales and marketing and also begin our acquisitive strategy,” said Michael Boyd, Executive Chairman of Jayex.

The company advises that it has utilised its placement capacity under 7.1 (7,363,698 shares) and 7.1A (17,636,302 shares).

Currently, a total amount of \$3 million is owing to major shareholder, Covenant Holdings (WA) Pty Ltd. Covenant is a company controlled by Jayex’s Executive Chairman, Michael Boyd. The Company has agreed, subject to Shareholder approval, to convert this debt owing under the Loan to Covenant into Convertible Notes. As advised on July 27, a general meeting will be held on September 29, 2020 via webcast to approve the issue of convertible notes.

Jayex Healthcare Limited
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205



Contacts for further information:

Executive Chairman

Michael Boyd
m.boyd@jayex.com
+44 (0) 731 210 6490

Media & Investor Relations

Kyahn Williamson
WE Communications
kwilliamson@we-worldwide.com
0401 018 828

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*[®] remote pharmacy prescription processing and dispensing terminal.

This announcement is authorised for release to the market by the Board of Directors of Jayex Healthcare Limited.